2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 117

Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 104

Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 583

Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 794

Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 103

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 811

Identification of Risk Factors for Gastric Antral Vascular Ectasia (GAVE) Among Systemic Sclerosis Patients

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 594

Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 681

Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 157

Identifying Additional Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Unique Cohort of Antiphospholipid Antibody Positive Chinese Patients

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 116

Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 511

Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 40

IFN Regulatory Factor 3 but Not IFN Regulatory Factor 7 Contributes to Bone Erosion in Collagen Induced Arthritis

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 168

IgG Anti-High-Density Lipoproteins Antibodies Discriminate between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 238

IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 317

Imaging Biomarker Based Patient Stratification: Initial Data and Validation in Four Most Common Knee Arthritic Diseases

Imaging of Rheumatic Diseases Poster I: MRI

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].